Pct

C4pitbull

New Member
sust250 / weeks 1-15 500mg a week

test prop / weeks 1-2 and 13-15 100mg e.o.d

eq / weeks 1-15 400mgs a week

what would be the best anti estrogen for pct ? and should i run any during the cycle
 
sust250 / weeks 1-15 500mg a week

test prop / weeks 1-2 and 13-15 100mg e.o.d

eq / weeks 1-15 400mgs a week

what would be the best anti estrogen for pct ? and should i run any during the cycle

Do not run any aromatase inhibitors (Arimidex, Letro, etc.) during PCT. Arimidex is always a safe bet during cycle to decrease water retention and combat gyno. Start with 0.5mg EOD and adjust based on your tolerance. I find that 1mg EOD results in very sore joints during workouts:(

For PCT just go with whatever you've used in the past. I think a combo of Nolva and Clomid will probably work better than either one by itself. Do a little research to find out about which dosages you'll need based on your cycle. When to start PCT is also important so do some further research on half lives of drugs based on Ester length. That will give you some idea of when to start your PCT. I could easily give you all of this info, but then you won't know why it's necessary to do what you're doing.

Along those same lines, I would finish the Sust by week 12 and then just shoot the prop for the last 3 weeks.

Cheers
 
Do not run any aromatase inhibitors (Arimidex, Letro, etc.) during PCT. Arimidex is always a safe bet during cycle to decrease water retention and combat gyno. Start with 0.5mg EOD and adjust based on your tolerance. I find that 1mg EOD results in very sore joints during workouts:(

For PCT just go with whatever you've used in the past. I think a combo of Nolva and Clomid will probably work better than either one by itself. Do a little research to find out about which dosages you'll need based on your cycle. When to start PCT is also important so do some further research on half lives of drugs based on Ester length. That will give you some idea of when to start your PCT. I could easily give you all of this info, but then you won't know why it's necessary to do what you're doing.

Along those same lines, I would finish the Sust by week 12 and then just shoot the prop for the last 3 weeks.

Cheers


Although it might already be known to most, I just wanted to reaffirm the finding of arthritis with AIs. As expected, most of the studies are in females. As for PCT, I am of the opinion for AIs to not be used for reasons previously explained.

Ohsako T, Inoue K, Nagamoto N, Yoshida Y, Nakahara O, Sakamoto N. Joint symptoms: a practical problem of anastrozole. Breast Cancer 2006;13(3):284-8. http://www.jstage.jst.go.jp/article/jbcs/13/3/284/_pdf

BACKGROUND: Anastrozole and tamoxifen have mild toxicity. However, we noticed that more patients treated with anastrozole complained of joint symptoms than expected. In particular, digital stiffness as is seen with rheumatoid arthritis is a problem. Some clinical trials of anastrozole in Europe and the United States reported musculoskeletal disorders as adverse events, however, joint symptoms were not described in detail.

PATIENTS AND METHODS: At our clinic from August 2001 to March 2005, 53 postmenopausal women with estrogen receptor-positive breast cancer were treated with anastrozole. We calculated the incidence and classified the grade of joint symptoms by interviewing patients. We also investigated the patients' characteristics and their relevance to joint symptoms.

RESULTS: Of 53 patients, 14 patients (26%) had joint symptoms (13 patients with digital stiffness and 3 patients with arthralgias of wrist and shoulders). Joint symptoms tended to occur in the patients who had previously undergone chemotherapy; however, there has no relationship between prior hormonal therapy and joint symptoms. Seven patients who discontinued anastrozole treatment showed improved symptoms. Five patients with grade 1 digital stiffness continued anastrozole treatment without additional treatment. Two patients with grade 1 digital stiffness, who took a Chinese herbal medicine showed improved symptoms and continued anastrozole treatment.

CONCLUSION: Benefits to the patients may possibly be lost by discontinuation of anastrozole or changing to tamoxifen since the clinical superiority of anastrozole to tamoxifen has been reported. We should continue anastrozole in patients with low grade symptoms, while ensuring that patients are aware of the toxicity of anastrozole.
 
Thanks for the advice Doc. Not to hijack the thread, but something else I think is important concerning AIs as well is liver toxicity. Can the toxicity to the liver of Anastrozole or Letrozole be adequately compared to any oral AAS (at an average dose, let's say...not mg per mg comparison)?

I could be off base here, but I do not like to run AIs and oral AAS concurrently for this reason. Not to mention that Winstrol in combo with Adex before I knew better almost crippled me for life.

Although it might already be known to most, I just wanted to reaffirm the finding of arthritis with AIs. As expected, most of the studies are in females. As for PCT, I am of the opinion for AIs to not be used for reasons previously explained.

Ohsako T, Inoue K, Nagamoto N, Yoshida Y, Nakahara O, Sakamoto N. Joint symptoms: a practical problem of anastrozole. Breast Cancer 2006;13(3):284-8. http://www.jstage.jst.go.jp/article/jbcs/13/3/284/_pdf

BACKGROUND: Anastrozole and tamoxifen have mild toxicity. However, we noticed that more patients treated with anastrozole complained of joint symptoms than expected. In particular, digital stiffness as is seen with rheumatoid arthritis is a problem. Some clinical trials of anastrozole in Europe and the United States reported musculoskeletal disorders as adverse events, however, joint symptoms were not described in detail.

PATIENTS AND METHODS: At our clinic from August 2001 to March 2005, 53 postmenopausal women with estrogen receptor-positive breast cancer were treated with anastrozole. We calculated the incidence and classified the grade of joint symptoms by interviewing patients. We also investigated the patients' characteristics and their relevance to joint symptoms.

RESULTS: Of 53 patients, 14 patients (26%) had joint symptoms (13 patients with digital stiffness and 3 patients with arthralgias of wrist and shoulders). Joint symptoms tended to occur in the patients who had previously undergone chemotherapy; however, there has no relationship between prior hormonal therapy and joint symptoms. Seven patients who discontinued anastrozole treatment showed improved symptoms. Five patients with grade 1 digital stiffness continued anastrozole treatment without additional treatment. Two patients with grade 1 digital stiffness, who took a Chinese herbal medicine showed improved symptoms and continued anastrozole treatment.

CONCLUSION: Benefits to the patients may possibly be lost by discontinuation of anastrozole or changing to tamoxifen since the clinical superiority of anastrozole to tamoxifen has been reported. We should continue anastrozole in patients with low grade symptoms, while ensuring that patients are aware of the toxicity of anastrozole.
 
Back
Top